Patients were randomised in a 1:1:1 fashion to
receive celecoxib (100 - 200 mg twice a day), ibuprofen (600 - 800 mg three times a day), or naproxen (375 - 500 mg twice a day) with matching placebos.
«Patients receiving ibuprofen had a 61 % higher incidence of de novo hypertension compared to
those receiving celecoxib,» said Professor Ruschitzka.
A significantly higher amount of stem cells had survived and integrated into the wound tissue in mice that had
received celecoxib, and there were fewer inflammatory white blood cells and lower levels of cytokines in their wounds, including one cytokine called interleukin - 17A.